Progranulin (PGRN) haploinsufficiency resulting from loss-of-function mutations in the PGRN gene causes frontotemporal lobar degeneration accompanied by TDP-43 accumulation, and patients with homozygous mutations in the PGRN gene present with neuronal ceroid lipofuscinosis. Although it remains unknown why PGRN deficiency causes neurodegenerative diseases, there is increasing evidence that PGRN is implicated in lysosomal functions. Here, we show PGRN is a secretory lysosomal protein that regulates lysosomal function and biogenesis by controlling the acidification of lysosomes. PGRN gene expression and protein levels increased concomitantly with the increase of lysosomal biogenesis induced by lysosome alkalizers or serum starvation. Down-regulation or insufficiency of PGRN led to the increased lysosomal gene expression and protein levels, while PGRN overexpression led to the decreased lysosomal gene expression and protein levels. In particular, the level of mature cathepsin D (CTSD mat ) dramatically changed depending upon PGRN levels. The acidification of lysosomes was facilitated in cells transfected with PGRN. Then, this caused degradation of CTSD mat by cathepsin B. Secreted PGRN is incorporated into cells via sortilin or cation-independent mannose 6-phosphate receptor, and facilitated the acidification of lysosomes and degradation of CTSD mat . Moreover, the change of PGRN levels led to a cell-type-specific increase of insoluble TDP-43. In the brain tissue of FTLD-TDP patients with PGRN deficiency, CTSD and phosphorylated TDP-43 accumulated in neurons. Our study provides new insights into the physiological function of PGRN and the role of PGRN insufficiency in the pathogenesis of neurodegenerative diseases.
Introduction
Progranulin (PGRN) is a multifunctional protein involved in pleiotropic actions including inflammation, tumorigenesis and sexual differentiation (1) (2) (3) . In the brain, PGRN haploinsufficiency resulting from heterozygous null or loss-of-function mutations in the PGRN gene (GRN) causes frontotemporal lobar degeneration (FTLD) characterized by ubiquitinated cytoplasmic inclusions containing TAR DNA-binding protein 43 kDa (TDP-43) (4-7). Furthermore, patients with a homozygous mutation in GRN present with neuronal ceroid lipofuscinosis (NCL), a group of lysosomal storage disorders (8) .
There is increasing evidence that PGRN is involved in the regulation of lysosomal function. GRN gene has two possible coordinated lysosomal expression and regulation (CLEAR) sequences in the promoter region, to which transcription factor EB (TFEB), a master regulator of lysosomal gene expression, binds and thereby increases GRN gene expression (9) . PGRN directly or indirectly binds to proteins that transport lysosomal proteins into lysosomes such as cation-independent mannose 6-phosphate receptor (CI-M6PR) or sortilin (SORT1) (10, 11) . Moreover, PGRN is localized to lysosomes, and suppresses exacerbated lysosomal biogenesis, especially in activated microglia after neuroinflammation or with aging in mice (12) (13) (14) (15) (16) . Aged PGRN-deficient mice exhibit selective vulnerability in the ventral posteromedial nucleus/ventral posterolateral nucleus region of the thalamus, as do model mice of lysosomal diseases (17, 18) . Interestingly, FTLD patients with PGRN haploinsufficiency present with typical pathological features of NCL, and mature cathepsin D (CTSD mat ), whose level is dependent on lysosomal function (19) , is accumulated in these diseases, suggesting that FTLD, as well as NCL resulting from PGRN insufficiency, is associated with lysosomal dysfunction. However, it remains unknown how PGRN regulates lysosomal function. Thus, in the present study, we investigated the regulatory function of PGRN.
Results

PGRN expression increases in MG6 and HeLa cells in which lysosomal biogenesis is induced by lysosome alkalizers or serum starvation
It is reported that lysosome alkalizer or serum starvation induces translocation of TFEB from cytoplasm to nucleus, followed by up-regulation of lysosomal genes (20, 21) . Since endogenous PGRN levels were higher and more clearly detectable in MG6 microglial cells and HeLa cells (Supplementary Materials, Figs S1 and S2), we used these cells to investigate whether PGRN expression increases in lysosomal biogenesis. We firstly confirmed PGRN expression in these cells and its co-localization with Lamp1, a lysosome marker ( Fig. 1A and B) . Then, we investigated whether PGRN expression increases in these cells exposed to lysosome alkalizers. In MG6 cells, the expression of the PGRN gene (Grn) as well as other lysosomal genes, Lamp1 gene (Lamp1) and cathepsin D gene (Ctsd), increased in the presence of lysosome alkalizers, 25 nM bafilomycin A1 (BafA1) or 100 lM chloroquine (CQ) for one day ( Fig. 1C and D) . In HeLa cells, the GRN expression did not increase in the presence of 25 nM BafA1 different from other lysosomal genes (Fig. 1E ). On the other hand, GRN and CTSD expressions increased in the presence of 100 nM BafA1, while the LAMP1 expression did not (Fig. 1F) . Immunoreactivity of Lamp1 and PGRN increased in MG6 cells exposed to 25 nM BafA1 (Fig.1G ) and HeLa cells exposed to 100 nM BafA1 (Fig.1H) . The PGRN levels also increased in these cells (Supplementary Material, Fig. S2 ). We next investigated the effect of serum starvation on PGRN levels. Immunoreactivity of Lamp1 and PGRN, and levels of PGRN and the pre-form of CTSD increased upon serum starvation for 5 days in MG6 cells ( Fig Fig. S4 ). We also estimated the effect of serum starvation on the acidification of lysosomes using cellpermeable dye, LysoSensor DND-189 or acridine orange. LysoSensor DND-189 fluorescence increases dependently on the acidity. Acridine orange monomer emits green fluorescence, whereas its dimer and oligomers formed when it is protonated emit red fluorescence. Consequently, the ratio of red/green fluorescence indicates the relative acidity of vesicles (22) . The acidification of lysosomes was facilitated in these cells by serum starvation (Supplementary Materials, Figs S5 and S6). Thus, these findings indicate that PGRN expression increases in lysosomal biogenesis induced by lysosome alkalizer or serum starvation in MG6 and HeLa cells.
Transient loss of PGRN leads to increase lysosomal protein and gene expression levels in HeLa and HEK293T cells
We next transiently down-regulated PGRN levels by siRNA treatment to investigate the effect of decreased levels of PGRN on lysosomal protein and gene expression levels. In HeLa cells, the down-regulation of PGRN led to increased LAMP1 and CTSD mat levels ( Fig. 3A and B) . LAMP1-positive area per cell was larger in HeLa cells transfected with GRN siRNA (Fig. 3C and D) . Further, expression of lysosomal genes such as LAMP1, CTSD and CTSB significantly increased in HeLa cells transfected with GRN siRNA (Fig. 3E) . In HEK293T cells, the down-regulation of PGRN led to increased LAMP1 levels. LAMP1 positive area per cell was larger in HEK293T cells transfected with GRN siRNA. PGRN deficiency leads to increase lysosomal protein and gene expression levels in primary microglial cells cultured under serum-free conditions Previous studies showed that growth factors regulate lysosomal biogenesis (20) . To investigate whether the regulation of lysosomal biogenesis by PGRN mediates that by growth factors, we examined the lysosomal protein and gene expression levels of primary microglia derived from wild-type (WT) or PGRN-deficient (KO) mice cultured under serum-free conditions for 5 days. PGRN was colocalized with Lamp1 in WT cells (Fig. 4A) . Then, PGRN was secreted into the culture medium by WT cells, but was not detected in the culture medium of KO cells (Fig. 4B ). Lamp1 immunoreactivity in KO cells was much higher than that of WT cells ( Fig. 4C and D) . Expression of Lamp1 and hexosaminidase A (Hexa) genes was also higher in KO cells (Fig. 4E) . Moreover, CTSD mat levels were higher in KO cells, and the addition of recombinant mouse PGRN (Rec) to the medium partially suppressed the increase of CTSD mat in KO cells, suggesting that secreted PGRN is incorporated into cells and suppresses the production of CTSD mat ( Fig. 4F and G) . Thus, these findings indicate that PGRN deficiency induces additional increases of lysosomal protein and gene expression levels under serum-free conditions in microglial cells, suggesting that PGRN regulates lysosomal biogenesis independently of growth factors.
Increased PGRN expression leads to decreased lysosomal protein and gene expression levels in SH-SY5Y cells
Since PGRN insufficiency led to increased lysosomal protein and gene expression levels, we next investigated the effect of increased PGRN expression on lysosomal protein and gene expression levels using human cells. In SH-SY5Y cells transfected with PGRN, exogenous PGRN was predominantly colocalized with calreticulin, a marker of endoplasmic reticulum (ER) (Supplementary Material, Fig. S9 ). PGRN was also colocalized with LAMP1 ( Fig. 5A ) and Ab1 (a marker of Golgi apparatus, Supplementary Material, Fig. S9 ). Under reducing conditions, the PGRN band shifted to higher molecular weight and showed greater reactivity with PGRN antibodies in immunoblotting (Supplementary Material, Fig. S10 ). Fractionation study indicated that PGRN was predominantly present in the membranerich fraction, like other lysosomal proteins. The level of CTSD mat was greatly decreased, and the level of LAMP1 was slightly decreased by PGRN expression (Fig. 5B) . On the other hand, LAMP1 levels increased in the cells exposed to alkalizer opposite to the case of PGRN expression (Supplementary Material, Fig. S11 ). Gene expression levels of CTSD and endogenous PGRN slightly decreased in SH-SY5Y cells transfected with PGRN (Fig. 5C ). Although the decrease of lysosomal protein and gene expression levels in response to PGRN expression was also detected in HEK293T and HeLa cells (Supplementary Materials, Figs S12 and S13), the decrease, especially that of CTSD mat , was most prominent in SH-SY5Y cells. Therefore, we further investigated lysosomal enzyme activity using SH-SY5Y cells. Enzyme activity assay showed that CTSD activity in the cells transfected with PGRN was remarkably decreased compared with mock cells (Fig. 5D and E). Recombinant human PGRN (hPGRN) did not directly affect the activities of CTSD purified from human liver or CTSD in cell lysate (Supplementary Material, Fig. S14 ). The activities of cathepsin B, K and L/S were also decreased in PGRN-expressing cells (Fig. 5E ). On the other hand, the activities of c-secretase and proteasome did not significantly change in cells transfected with PGRN (Fig. 5E,  Supplementary Material, Fig. S15 ). Thus, these findings indicate that PGRN expression leads to decreased lysosomal protein and gene expression levels, especially in SH-SY5Y cells.
PGRN expression facilitates acidification in lysosomes
The action of PGRN expression to down-regulate lysosomal protein and gene expression levels was opposite to the effect of lysosome alkalizers. It is noteworthy that the decrease of CTSD mat by PGRN expression was a characteristic and common phenotype among the cell lines examined. Therefore, we investigated whether BafA1 counteracts the decrease of CTSD mat in SH-SY5Y cells transfected with PGRN, because the effect of PGRN expression on the decrease of CTSD mat was most prominent in SH-SY5Y cells. In the presence of 1 nM BafA1 for 3 days after transfection, the level of PGRN slightly increased, and the decrease of CTSD mat induced by PGRN expression was partially reversed (Fig. 6A-C) . A higher concentration of BafA1 (10 nM) resulted in a remarkable increase of the level of PGRN, and suppressed the conversion of CTSD pre to CTSD mat ( Fig. 6D-F) . Furthermore, PGRN expression counteracted the decrease of cell viability induced by disturbed lysosomal acidification in cells transfected with PGRN for 2 days followed by exposure to 1 nM BafA1 for 2 days (Supplementary Material, Fig. S16 ). Thus, ectopic expression of PGRN caused the decrease of CTSD mat , which was counteracted by BafA1. This result led us to investigate the acidification of lysosomes in cells expressing PGRN. We evaluated the influence of PGRN expression on the acidification of lysosomes by the use of acridine orange in SH-SY5Y, HEK293T and HeLa cells. As shown in Figure 7A , acridine orange monomer emits green fluorescence, whereas its dimer and oligomers emit red fluorescence. The red/green fluorescence ratio was highest in HeLa cells, followed in order by HEK293T and SH-SY5Y cells, indicating that the acidity of the vesicles was highest in HeLa cells, followed by HEK293T and then SH-SY5Y cells. Interestingly, PGRN expression enhanced the red/ green fluorescence ratio in these cells, indicating that PGRN expression facilitates acidification of vesicles in these cells, while BafA1 suppressed the formation of the dimer and oligomers (which emit red fluorescence), confirming its action as an alkalizer (Fig. 7B, Supplementary Material, Fig. S17 ). We further evaluated the acidification of lysosomes using a pyridyl oxazole probe, Lysosenor Yellow/Blue DND-160 in SH-SY5Y cells. The pH of the cells transfected with PGRN was lower at 48, 60 and 72 h after transfection (Fig. 7C) , and growth of cells transfected with PGRN was slower (Fig. 7D) . To enable visual evaluation of the acidity of lysosomes in cells expressing PGRN, we prepared IRES bicistronic plasmid expressing PGRN and mCherry separately (PGRN-IRES-mCherry). As shown in Figure 7E , the cell transfected with this plasmid expressed mCherry and exogenous PGRN. The molecular weight of PGRN isolated from cells transfected with PGRN-IRES-mCherry was similar to that in cells transfected with PGRN in western blotting. The mCherry was highly accumulated in cells transfected with PGRN-IRESmCherry compared with cells transfected with IRES-mCherry (Fig. 7F) . We visually evaluated the acidification of lysosomes in SH-SY5Y cells transfected with IRES-mCherry or PGRN-IRESmCherry using LysoSensor DND-189, which shows decreased (Fig. 5B,  Supplementary Material, Fig. S13) . Nevertheless, the level of CTSD mat decreased in HEK293 cells transfected with PGRN. Therefore, the decrease of CTSD mat by PGRN expression might be partially mediated by its degradation. We investigated whether lysosomal enzymes are involved in the decrease of CTSD mat in SH-SY5Y cells transfected with PGRN. Cells transfected with PGRN for 3 days were exposed to AEBSF (a serine protease inhibitor), E-64 (a cysteine protease inhibitor) or pepstatin A (an aspartic protease inhibitor) for a day before sampling. AEBSF did not restore the level of CTSD mat . E-64 dosedependently restored the level of CTSD mat in cells transfected with PGRN. Pepstatin A also restored the level of CTSD mat in cells transfected with PGRN (Fig. 8A) . Considering that pepstatin A did not influence the level of purified human CTSD mat upon incubation in acetate buffer (pH 4) at 40 C (Supplementary Material, Fig. S22 ), the decrease of CTSD mat in cells expressing PGRN is not likely to be due to self-degradation of CTSD mat . Pepstatin A binds to CTSD mat and stabilizes it (23, 24) . Therefore, the increase of CTSD mat in cells transfected with PGRN and exposed to pepstatin A is likely associated with increased stability of CTSD mat . Thus, we next focused on the effect of major cysteine proteases in lysosomes on the CTSD mat degradation in cells transfected with PGRN. Cells were exposed to CA074Me (cathepsin B inhibitor), CTSL-I (cathepsin L inhibitor) or CTSS-I (cathepsin S inhibitor) for one day before sampling. CTSL-I and CTSS-I led to increased levels of CTSD mat both in mock and PGRN-transfected cells, whereas CA074Me partially increased CTSD mat only in PGRN-transfected cells ( Fig. 8B and C) . Values are the mean 6 SEM (n ¼ 3), *P < 0.05, unpaired t-test.
Moreover, CTSD mat degradation was inhibited in cells transfected with PGRN and exposed to CA074Me for 3 days, even though the level of PGRN was increased ( Fig. 9A and B) . Similarly, the down-regulation of CTSB by siRNA led to a decrease of mature CTSB ( Fig. 9D ). CTSB-catalyzed hydrolysis is pH-dependent (25) . Therefore, we investigated the effect of pH on the degradation of CTSD mat by CTSB in lysate from SH-SY5Y cells. In the presence of CA074Me, the degradation of CTSD mat was inhibited only at pH 4, but not at pH 5 or pH 6, indicating that CTSB hydrolyzed CTSD mat at lower pH. On the other hand, addition of recombinant hPGRN to the cell lysate did not decrease the level of CTSD mat ( Fig. 9E and F). These findings indicate that CTSD mat is at least degraded by CTSB in cells transfected with PGRN, probably because lysosomal acidification is promoted by PGRN expression.
Secreted PGRN leads to decrease of mature cathepsin D in SH-SY5Y cells PGRN transported into lysosomes by cationindependent mannose 6-phosphate receptor or sortilin facilitates the acidification of lysosomes in SH-SY5Y cells
Transport of PGRN into lysosomes is partially mediated by cation-independent mannose 6-phosphate receptor (CI-M6PR) or sortilin (SORT1) (11) . To investigate the effects of these proteins on PGRN transport, cells were transfected with plasmid (pcDNA or PGRN) and siRNA (control, CI-M6PR or SORT1). As shown in Figures 11A and 12A, exogenous PGRN was colocalized with CI- M6PR or SORT1, respectively, and down-regulation of either of them led to decreased PGRN co-localization. Although downregulation of CI-M6PR led to an increase of PGRN ( Fig. 11B and C) , down-regulation of SORT1 led to a decrease of PGRN ( 13A-C). Furthermore, the number of DND-189-positive puncta decreased in these cells ( Fig. 13D and E) . Thus, these findings indicate that both CI-M6PR and SORT1 mediate incorporation of PGRN, thereby facilitating lysosomal acidification and CTSD mat reduction.
PGRN expression influences detergent-insoluble TDP-43 accumulation in cells
Although PGRN expression facilitated the acidification of lysosomes in SH-SY5Y, HEK293T and HeLa cells, PGRN levels and the acidity of lysosomes were different among the cell lines. Therefore, the influence of up-regulation or down-regulation of PGRN on TDP-43 insolubility or phosphorylation might be Table S1 ). We found cells accumulating CTSD and pTDP-43 in the affected region of the cerebral cortex of the patients (Fig.   15A, Supplementary Material, Fig. S27 ). Moreover, doubleimmunostaining of CTSD and GFAP (an astrocyte marker), Iba1 (a microglial marker), or NeuN (a neuron marker) showed that CTSD predominantly accumulates in neurons (Fig. 15B,  Supplementary Material, Fig. S27 ). These findings suggest that deficiency of PGRN might have a prominent role in the appearance of lysosomal dysfunction with aging in human neuronal cells, as well as the associated accumulation of phosphorylated TDP-43.
Discussion
In the present study, PGRN expression increased in association with lysosomal biogenesis induced by lysosome alkalizers or serum starvation. Additionally, PGRN insufficiency led to increase lysosomal protein and gene expression levels, as seen in HeLa and HEK293T cells in which PGRN was transiently downregulated, or microglia from PGRN-deficient mice cultured under serum-free conditions, indicating that PGRN insufficiency induces lysosomal biogenesis. Conversely, PGRN overexpression led to decreased lysosomal protein and gene expression levels, indicating that PGRN overexpression suppresses lysosomal biogenesis. Thus, the level of PGRN in cells appears to be an important determinant of lysosomal biogenesis.
Lysosomal biogenesis is primarily regulated by TFEB (9). Translocation of TFEB from cytoplasm to nucleus up-regulates lysosomal gene expression (27) . As shown in the previous study, growth factors phosphorylate TFEB, thereby blocking translocation of TFEB from the cytoplasm to the nucleus, and suppressing lysosomal biogenesis (20) . On the other hand, our present findings indicate that PGRN insufficiency leads to lysosomal biogenesis in cells cultured with or without serum, suggesting that the regulation of lysosomal biogenesis by PGRN is distinct from the ERK-mediated regulation by growth factors (20) . TFEB phosphorylation is also mediated by mammalian target of rapamycin complex 1 (mTORC1), and mTORC1 phosphorylation is partially regulated by the lysosomal environment (21) . Although PGRN expression did not enhance mTORC1 phosphorylation (Supplementary Material, Fig. S28 ), disturbed lysosomal acidification resulting from PGRN insufficiency might decrease the phosphorylation level. Indeed, we previously demonstrated that mTORC1 phosphorylation is decreased in PGRN-deficient mice, which in turn increased lysosomal biogenesis due to increased nuclear localization of TFEB in activated microglia of mice (13) . Further studies are needed to elucidate the mechanism of lysosomal biogenesis mediated by PGRN.
Lysosomal acidification is essential for the digestive function and to drive efflux of digested materials (28) . An increase in the pH of lysosomal organelles prevents secretory behavior of acidic vesicles and leads to accumulation of acidic vesicles within the cell cytoplasm (29) . Importantly, our aged PGRN-deficient mice showed marked accumulation of lipofuscin, an end-product of lysosomal digestion in the thalamus, and microglia were round or amoeboid with vacuole-like structures (18, 30, 31) . Moreover, null mutations in GRN greatly reduce the number of released exosomes and alter their composition (32) . These findings indicate that PGRN deficiency suppresses digestion in and efflux from lysosomes. Disturbed lysosomal acidification resulting from PGRN deficiency might contribute to these disorders. Lysosomal acidification is mainly regulated by vacuolar-type H þ -ATPase (V-ATPase), which transports protons across the membrane. V-ATPase consists of two functionally distinct V 0 transmembrane domains and the V 1 cytosolic domain, and the activity of V-ATPase depends on their dynamic assembly (33). We did not detect any significant effect of PGRN expression on the amounts of ATP6V0C and ATP6V1C1 in the membrane fraction in the present study (Supplementary Material, Fig. S28 ). Therefore, PGRN might affect the function of V-ATPase rather than its amount. Further studies will be needed to elucidate the mechanism through which PGRN regulates lysosomal acidification.
We also found that the phenotype resulting from PGRN expression is mediated by secreted PGRN. The addition of PGRN to the medium facilitated mature CTSD reduction, similarly to PGRN overexpression. This reduction is mediated by lysosomal acidification, which at least induces mature CTSD degradation by CTSB in PGRN-rich cells. Previously, we indicated that astrocytes or oligodendrocytes in aged PGRN-deficient mice accumulate p62 aggregates, though PGRN expression in these cells was not detected by immunohistochemistry (18) . These findings suggest that PGRN secreted from neurons or microglia is incorporated into various cells in the brain, and counteracts lysosomal dysfunction due to aging by facilitating the acidification of lysosomes. Thus, we suggest that PGRN is a secretory lysosomal protein that facilitates the acidification of lysosomes (Fig. 16) .
Down-regulation of CI-M6PR, but not SORT1, increased intracellular PGRN levels in cells transfected with PGRN, suggesting that CI-M6PR directly transports intracellularly produced PGRN into lysosomes in SH-SY5Y cells. On the other hand, both SORT1 and CI-M6PR mediated the transport of PGRN from outside of the cells into lysosomes in the cells. Under neuroinflammatory conditions (e.g. neurodegenerative diseases), activated microglia predominantly produce PGRN (13, 34) . Although the mechanism of incorporation of extracellular PGRN into activated microglia is still unclear, Sort1 expression was not detected by immunohistochemistry in CD68-positive activated microglia of mice (Supplementary Material, Fig. S29 ), suggesting that PGRN secreted from activated microglia might improve the supply of PGRN to other glial cells and neurons.
Phosphorylated TDP-43 accumulation is a distinctive characteristic of FTLD resulting from PGRN deficiency (26) . We found that CTSD as well as phosphorylated TDP-43 was accumulated in neurons of the affected region in the brain from PGRNdeficient FTLD patients, suggesting that TDP-43 accumulation is implicated in lysosomal dysfunction in neurons. Interestingly, up-regulation or down-regulation of PGRN caused increased accumulation of detergent-insoluble TDP-43 in cells, and this TDP-43 accumulation was cell-type-specific. The finding that detergent-insoluble TDP-43 increases in SH-SY5Y and HEK293T cells in which PGRN is down-regulated, but does not increase in HeLa cells, suggests that cells with lysosomes of lower acidity might accumulate TDP-43 as a result of PGRN deficiency. Additionally, the finding that detergent-insoluble TDP-43 increases in SH-SY5Y cells in which PGRN is up-regulated or down-regulated suggests that the disturbed lysosomal function due to the altered acidity of the lysosomes might lead to TDP-43 accumulation (Supplementary Material, Fig. S30 ). Although it is not clearly known why lysosomal dysfunction would cause accumulation of detergent-insoluble TDP-43, the formation of TDP-43 fibrils might be a key to the pathogenesis of FTLD-TDP (26), because proteasome hardly degrades protein fibrils (35) and PGRN insufficiency causes FTLD-TDP, but not FTLD characterized by tau accumulation. Although it is largely unknown when or how TDP-43 fibrillization starts, previous studies have shown that profilin 1 aggregates provide a scaffold for conformational changes of TDP-43 (36, 37) . Considering that TDP-43, but not other aggregation-prone proteins such as tau or a-synuclein, predominantly accumulates in PGRN-insufficient human brain, lysosomal dysfunction might lead to the formation of a scaffold, such as profilin 1 aggregates, upon which conformational change of TDP-43 can occur. Overall, our findings highlight the importance of lysosomal function in the pathogenesis of neurodegenerative diseases.
Materials and Methods
Antibodies and reagents
Anti-cathepsin B (CTSB) antibody (ab58802), anti-EEA1 antibody (ab2900), monoclonal and polyclonal anti-LAMP1 antibodies (ab25630 and ab24170), monoclonal anti-cation-independent mannose 6-phosphate receptor (CI-M6PR) antibody (ab2733), monoclonal rabbit anti-human PGRN antibody (ab108608) and anti-sortilin antibody (ab16640) were purchased from Abcam. Rat anti-Lamp1 antibody (553792) was purchased from BD Bioscience. Anti-cofilin antibody (ACFL02) was purchased from Cytoskeleton. Anti-mCherry antibody (GTX128508) was purchased from GeneTex. Biotin-conjugated donkey anti-rat IgG antibody (712-065-153) was purchased from Jackson ImmunoResearch Laboratories. Anti-GAPDH antibody (MAB374), anti-GFAP antibody (04-1062) and anti-NeuN antibody (MAB377) were purchased from Millipore. Polyclonal anti-CI-M6PR antibody (20253-1-AP) and monoclonal anti-TDP-43 antibody (60019-2) were purchased from ProteinTech. Polyclonal sheep anti-mouse PGRN antibody (AF2557) was purchased from R&D Systems. Anti-cathepsin D (CTSD) antibody (sc-6486) and polyclonal goat anti-human PGRN antibody (sc-11342) were purchased from Santa Cruz Biotechnology. Anti-a-tubulin antibody (T5168) was purchased from Sigma. Biotin-conjugated horse anti-mouse (BA-2000), goat anti-rabbit (BA-1000) and rabbit anti-goat (BA-5000) IgG antibodies were purchased from Vector Laboratories. Alexa Fluor 488 or 568-conjugated secondary antibodies, and Alexa Fluor 568-conjugated streptavidin were purchased from Thermo Fisher Scientific. AntiIba1 antibody (016-20001) was purchased from Wako. Polyclonal anti-pTDP-43 antibody specific for Ser409/410 were prepared as described (26, 38) Recombinant mouse (AG-40A-0189) and human (AG-40A-0188Y) untagged progranulin produced from HEK293 cells by affinity purification, and mouse progranulin ELISA kit (AG-45A-0019YEK-KI01) were purchased from Adipogen. Acridine orange (#6130) was purchased from ImmunoChemistry Technologies. Cathepsin S inhibitor (219393) was purchased from Millipore. Pepstatin A and CA074Me were purchased from Peptide Institute. Chloroquine and E-64 were purchased from Sigma. Cathepsin L inhibitor (SC-3132) was purchased from Santa Cruz Biotechnology. LysoSensor Green DND-189, LysoSensor Yellow/Blue DND-160 and LysoTracker Red DND-99 were purchased from Thermo Fisher Scientific. AEBSF and bafilomycin A1 were purchased from Wako.
Culture of MG6 cells, SH-SY5Y cells and primary microglia
MG6 cells (39, 40) were provided by the RIKEN BRC cell bank (Tsukuba, Japan). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma) containing 10% fetal calf serum (FCS), 1% penicillin/streptomycin (P/S) (Thermo Fisher Scientific), 10 lg/ml insulin (Sigma), and 0.1 mM 2-mercaptoethanol (2-ME) (Nacalai Tesque), and maintained at 37˚C in the presence of 5% (v/v) CO 2 .
SH-SY5Y neuroblastoma cells, not neuronally differentiated, were cultured in DMEM/F12 medium (Sigma) supplemented with 10% (v/v) FCS, 1% P/S, and MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific), and maintained at 37 C in the presence of 5% (v/v) CO 2 . HeLa and HEK293T cells were cultured in DMEM medium (Sigma) supplemented with 10% (v/v) FCS, 1% P/S, and MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific), and maintained at 37 C in the presence of 5% (v/v) CO 2 . Primary microglia were isolated from the cerebral cortex of newborn wild-type (WT) or PGRN-deficient (KO) mice (41) at one or two days after parturition. Brains from individual animals were placed in ice-cold L15 medium (Thermo Fisher Scientific) containing 0.1% BSA (sigma) and 1% penicillin-streptomycin. Meninges were removed, cerebral cortices were dissected, and cells were dissociated with a cell strainer (100 lm pore size, BD Bioscience). Dissociated cells were seeded at a density of 2.5 Â 10 5 cells per 10 cm dish, and cultured in DMEM containing 10% FCS and 1% P/S. The medium was replaced every 4-5 days, and cells were cultured in the presence of 5% CO 2 for 21 days in vitro (DIV21). On DIV 21, adherent microglial cells on the bottom of the dish were isolated by mild trypsinization as previously described (42) . 
Expression vectors
The expression vectors for cells used in this study were as follows: pcDNA3.1 (þ) (Thermo Fisher Scientific), pcDNA3.1 (þ)-PGRN, pIRES2-mCherry, pIRES2-PGRN-mCherry. pIRES2-mCherry vector was constructed from pIRES2-AcGFP1 (Clonetech). To construct pIRES2-mCherry plasmid, a cDNA encoding mCherry was amplified from pmCherry-C1 (Clonetech) using the following primers (mCherry forward; 5'-AAT ATG GCC ACA ACC ATG GTG AGC AAG GGC GAG GA-3', mCherry reverse; 5'-TCT AGA GTC GCG GCC TCA CTT GTA CAG CTC GTC CA-3'). The amplified fragment was digested with BxtXI and NotI and cloned into the same cleavage sites of the vector by In-Fusion reaction (Clonetech). To construct pcDNA3.1 (þ)-PGRN plasmid, a cDNA encoding full-length human PGRN was amplified from cDNA extracted from human neuroblastoma SH-SY5Y using the following primers (PGRN forward; 5'-CGG AAT TCA TGT GGA CCC TGG TGA GCT GG-3', PGRN reverse; 5'-GCT CTA GAT CAC AGC AGC TGT CTC AAG G-3'). The amplified fragment was digested with EcoRI and XbaI and cloned into the same cleavage sites of the vector. To construct pIRES2-PGRN-mCherry plasmid, a cDNA encoding full-length human PGRN was amplified from pcDNA3.1 (þ)-PGRN plasmid using the following primers (PGRN forward; 5'-CTC AAG CTT CGA ATT ATG TGG ACC CTG GTG AGC TGG-3', PGRN reverse; 5'-GTC GAC TGC AGA ATT TCA CAG CAG CTG TCT CAA GG-3'). The amplified fragment was digested with EcoRI and cloned into the same cleavage sites of the vector by In-Fusion reaction (Clonetech). All constructs were verified by DNA sequencing.
Gene overexpression and RNA interference
Cells were grown to 30-40% confluence in collagen-coated sixwell plates. For gene overexpression, cells were transfected with expression vectors using X-tremeGENE 9 DNA Transfection Reagent (Roche) according to the manufacturer's instructions. For RNA interference, cells were transfected with siRNA using X-tremeGENE siRNA Transfection Reagent (Roche) according to the manufacturer's instructions. For PGRN overexpression and RNA interference, cells were co-transfected with pcDNA3.1 (þ)-PGRN and siRNA with X-tremeGENE siRNA Transfection Reagent (Roche) according to the manufacturer's instructions. siRNA duplexes (Thermo Fisher Scientific) designed to target human GRN (HSS104450: forward, 5'-AGA UCG UGG CUG GAC UGG AGA AGA U-3'; reverse, 5'-AUC UUC UCC AGU CCA GCC ACG AUC U-3'), CTSB (s3739: forward, 5'-AGA GAG UUA UGU UUA CCG ATT-3'; reverse, 5'-UCG GUA AAC AUA ACU CUC UGG-3'), SORT1 (HSS109430: forward, 5'-CCA AGU CUU UGG ACC GAC AUC UCU A-3'; reverse, 5'-UAG AGA UGU CGG UCC AAA GAC UUG G-3') and IGF2R (CI-M6PR) (HSS105258: forward, 5'-GCA CGA CUU GAA GAC ACG CAC UUA U-3'; reverse, 5'-AUA AGU GCG UGU CUU CAA GUC GUG C-3') were used. Stealth RNAi Negative Control Duplexes (Med GC Duplex #3, Thermo Fisher Scientific) were used as a negative control of siRNA. 
ELISA
A mouse progranulin ELISA kit (Adipogen) was used according to the manufacturer's instructions to measure PGRN levels in culture medium of primary microglia.
Real-time PCR
Total RNA was isolated from cells with TRIzol (Invitrogen), and first-strand cDNA was synthesized with SuperScriptII reverse transcriptase (Invitrogen). PCR reactions were performed with Thunderbird SYBR qPCR MIX (Toyobo) and a LightCycler (Roche) or CFX96 (Bio-Rad), with the following primers: mouse progranulin (Grn) (forward, 5'-TGG CTA ATG GAA ATT GAG GTG-3'; reverse, 5'-CAT CAG GAC CCA CAT GGT CT-3'), mouse lysosomal-associated membrane protein 1 (Lamp1) (forward, 5'-CCT ACG AGA CTG CGA ATG GT-3'; reverse, 5'-CCA CAA GAA CTG CCA TTT TTC-3'), mouse cathepsin D (Ctsd) (forward, 5'-CCC TCC ATT CAT TGC AAG ATA C-3'; reverse, 5'-TGC TGG ACT TGT CAC TGT TGT-3'), mouse hexosaminidase A (Hexa) (forward, 5'-ACC TGG GAG GGG ATG AAG T-3'; reverse, 5'-ATG AAG GCC TGG ATG TTG G-3'), mouse hypoxanthine phosphoribosyltransferase (Hprt; an internal standard) (forward, 5'-CCT CCT CAG ACC GCT TTT T-3'; reverse, 5'-AAC CTG GTT CAT CAT CGC TAA-3'), human endogenous progranulin (GRN) (forward, 5'-TCT GTA GTC TGA GCG CTA CCC-3'; reverse, 5'-AGGGTCCACATGGTCTGC-3'), human lysosomal-associated membrane protein 1 (LAMP1) (forward, 5'-CCA ACA GCA GCT TCA GCA-3'; reverse, 5'-TGT CCA CAG AGG GGC TCT T-3'), human cathepsin D (CTSD) (forward, 5'-CAT CTT CTC CTT CTA CCT GAG CA-3', reverse; 5'-GTC TGT GCC ACC CAG CAT-3'), human cathepsin B (CTSB) (forward, 5'-CTG TGG CAG CAT GTG TGG-3', reverse; 5'-TCT TGT CCA GAA GTT CCA AGC -3') and human hypoxanthine phosphoribosyltransferase (HPRT; an internal standard) (forward, 5'-TGA CCT TGA TTT ATT TTG CAT ACC-3'; reverse: 5'-CGA GCA AGA CGT TCA GTC CT-3'). The PCR reactions were carried out as follows: 1 min at 95 C for the initial denaturation, followed by 40 cycles of amplification at 95 C for 15 s and 60 C for 60 s. Expression levels of genes of interest were normalized to Hprt or HPRT.
Immunocytochemistry
Primary microglia grown on 8-well microchamber plates (BD Biosciences) were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min on DIV 27. After blocking with PBS containing 0.3% (v/v) Triton X-100 (PBST) and 5% (v/v) normal goat serum (Sigma) at room temperature (RT) for 30 min, cells were exposed to primary antibodies at RT overnight. For PGRN immunostaining, the cells were incubated with an Alexa 488-conjugated secondary antibody at RT for 1 h (Invitrogen). For Lamp1 immunostaining, the cells were incubated with a biotin-conjugated secondary antibody (Jackson ImmunoResearch Laboratories) at RT for 1 h, followed by incubation with Alexa 594-conjugated streptavidin (Invitrogen) at RT for 1 h. Nuclei were stained with Hoechst33258 (Polysciences) at RT for 30 min. Samples were analyzed using a BX50 fluorescence microscope (Olympus) or a LSM780 confocal laser microscope (Carl Zeiss). For quantitative analysis of Lamp1 immunoreactivity, 50 to 100 microglia were randomly selected and photographed under the fluorescence microscope with a 20x magnification objective lens, and their fluorescence intensities were dissected using ImageJ (NIH). MG6, HeLa and SH-SY5Y cells grown on collagen-coated coverslips were fixed with 4% paraformaldehyde in PBS for 30 min. The coverslips were then incubated in 50 mM NH 4 Cl in PBS for 10 min and cell permeabilization was performed with 0.2% (v/v) Triton X-100 in PBS for 10 min. After blocking for 30 min in 5% (w/v) BSA in PBS, cells were incubated with the primary antibody at 37 C for 1 h. The cells were washed and further incubated with Alexa 488-or 568-conjugated secondary antibody at 37 C for 1 h, and then with Hoechst 33342 (Lonza) to counterstain nuclear DNA. Samples were analyzed using a BZ-X710 fluorescence microscope (Keyence) or a LSM780 confocal laser microscope (Carl Zeiss). Immunohistochemistry for brain slices of PGRNdeficient FTLD patients Table S1 ). The sections were blocked with PBS containing 0.3% Triton X-100 and 10% calf serum, and exposed to primary antibody at room temperature overnight. Sections were exposed to Alexa Fluor 488-or 568-conjugated secondary antibody at room temperature for 2 h. Nuclei were stained with Hoechst 33342 at room temperature for 60 min. All sections were mounted on glass slides and coverslipped with ProLong Gold antifade reagents (Life Technologies). Sections were examined under an LSM 780 laser scanning confocal microscope (Carl Zeiss).
Protein extraction and western blotting
Primary microglia on DIV 27 were lysed in a solution containing 2% (w/v) sodium dodecyl sulfate (SDS), 6% (v/v) 2- mercaptoethanol (ME), 10% (w/v) glycerol and 50 mM Tris-Cl (pH 6.8). MG6 cells were lysed in a solution containing 2.5% SDS, 30% (w/v) glycerol and 125 mM Tris-Cl (pH6.8). HeLa, HEK293T and SH-SY5Y cells were lysed in a solution containing 1 mM EDTA, 100 mM NaCl, 0.1% CHAPS, 0.1% protease inhibitor cocktail (Millipore) and 50 mM HEPES (pH 7.5), and further mixed with SDS-sample buffer (10% SDS, 400 mM Tris-HCl, 30% glycerol, and 50 mM dithiothreitol (DTT) or 5% 2-ME (pH 7.5)) to a final concentration of 2% SDS. SH-SY5Y cells were also separated into membrane-rich fraction and cytosolic fraction. Briefly, cells were mildly lysed with fractionation buffer (10 mM Tris-HCl, 250 mM sucrose (pH 6.8)) using a BioMasher (Nippi) on ice. After centrifugation at 800 Â g for 10 min at 4 C to remove nuclei and cell debris, the supernatants were pooled and centrifuged at 100000 Â g for 1 h at 4 C. The supernatants were collected as the cytosolic fraction. The membrane pellet was washed once in fractionation buffer, and recollected by centrifugation at 100000 Â g for 30 min at 4 C. Membranes were resuspended in lysis buffer and used as the membrane-rich fraction. Proteins were also extracted from the culture medium. Briefly, the medium was diluted with four volumes of cold acetone, and incubated at -20 C overnight. After centrifugation at 12000 Â g for 10 min, the protein pellet was dried for 10 min. The pellet was lysed in a solution containing 1 mM EDTA, 100 mM NaCl, 0.1% CHAPS, 0.1% protease inhibitor cocktail (Millipore) and 50 mM HEPES (pH 7.5). For sequential extraction of protein, cells were lysed in 1% (w/v) Sarkosyl in A68 [10 mM Tris-HCl buffer, pH 7.5, 0.8 M NaCl, 1 mM ethylene glycol bis(b-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA)]. The lysates were centrifuged at 290,000g for 20 min at room temperature (RT). The supernatant was collected as the Sarkosyl-soluble fraction (sup). The remaining pellets were lysed in SDS-sample buffer (2% SDS, 160 mM Tris-HCl, 30% glycerol (pH 7.5)) (ppt). Protein concentration in the cell lysate was estimated using a BCA Protein Assay Kit (Thermo Fisher Scientific), and SDS-sample buffer was added to give a final concentration of 2% SDS. Samples were boiled for 5 min and separated by SDS-PAGE, and bands were transferred onto polyvinylidene difluoride membrane (Millipore). The blots were blocked with 3% (w/v) gelatin (Wako) or Blocking One (Nacalai Tesque), and incubated overnight with the indicated primary antibody in Tris-buffer containing 10% (v/ v) calf serum at RT. The membranes were washed, and incubated with a biotin-conjugated secondary antibody (Vector) or a horseradish peroxidase-labeled secondary antibody (Bio-rad) for 2 h at RT. Signals were detected using the ABC staining kit (Vector) or ECL Prime Western Blotting Detection System (GE Healthcare). The digitized images were analyzed using ImageJ (NIH).
Enzyme activity assay
Fluorogenic substrates were used to measure enzyme activities in cell lysate. To measure cathepsin B (CTSB), cathepsin D (CTSD), cathepsin K (CTSK) or cathepsin L/S (CTSL/CTSS) activity, SH-SY5Y cells transfected with pcDNA3 or PGRN for 3 days were lysed with 50 mM acetate buffer (pH 4.0 for CTSD), 50 mM acetate buffer containing 5 lM pepstatin A (Peptide Institute), 1 mM AEBSF (Wako), 1 mM EDTA and 5 mM DTT (pH 5.5 for CTSK), or 50 mM potassium phosphate buffer containing 5 lM pepstatin A (Peptide Institute), 1 mM AEBSF (Wako), 1 mM EDTA, and 5 mM DTT (pH 6.0 for CTSB, pH 6.5 for CTSL/CTSS) on ice. c-Secretase activity was measured as described previously (45); cells were mildly lysed with membrane isolation buffer (20 mM HEPES, 50 mM KCl and 2mM EGTA (pH 7.5)) using a BioMasher (Nippi) on ice. After centrifugation at 800 Â g for 10 min at 4 C to remove nuclei and cell debris, the supernatants were pooled and centrifuged at 100000 Â g for 1 h. The membrane pellet was washed once in membrane isolation buffer, and recollected by centrifugation at 100000 Â g for 30 min. Membranes were resuspended in membrane solubilization buffer (20 mM HEPES, 150 mM KCl, 2 mM EGTA and 1% (w/v) CHAPS (pH 7.0)) by rotation for 1 h. Protein concentrations in cell lysate were estimated using the BCA Protein Assay Kit (Thermo Fisher Scientific). For CTSD, the reaction was started by mixing 10 ll of lysate, 87 ll buffer, 1 ll of DMSO or 1 mM pepstatin A with 2 ll of 1 mM substrate solution 
Measurement of lysosomal pH
Lysosomal pH was measured as described previously (46) . For quantification of lysosomal pH, a ratiometric lysosomal pH dye LysoSensor Yellow/Blue DND-160 was used. Briefly, cells were labeled with 2 lM LysoSensor Yellow/Blue DND-160 for 30 min at 37 C, and harvested with pH 7.0 MES buffer (25 mM MES, 
Cell counting
Cell counts were determined by the trypan blue dye exclusion method using an automated cell counter TC10 (Bio-rad).
Ultrafiltration of cultured medium 2 ml of DMEM/F12 medium, in which SH-SY5Y cells transfected with pcDNA3 or PGRN had been cultured for 3 days, was concentrated to about 100 ll by ultrafiltration using Amicon Ultra 2 ml (Millipore) according to the manufacturer's instructions. The concentrated medium was diluted to 2 ml with fresh 
